Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
IdMo
South San Francisco, California, United States
- Ownership
- Private
- Employees
- ~400
- Development stage
- Other
01
Overview
Cellares’ IDMO model and Cell Shuttle platform enable fully automated, closed, and scalable manufacturing of cell therapies (e.g., CAR-T, CRISPR-edited cell therapies); FDA AMT designation; partnerships with major biopharma for clinical, commercial adoption
- Therapeutic areas
- OncologyImmunology
- Modalities
- Cell therapy (especially CAR-T)CRISPR-based therapyBiologic
- Industry
- Contract Manufacturing Organization
02
Partnerships
Bristol Myers SquibbLyell ImmunopharmaCabaletta BioUniversity of Wisconsin School of Medicine and Public HealthMitsui Fudosan (Japan facility)
Beyond the preview
Go deeper on IdMo.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IdMo.